Macrophages: Potential Therapeutic Target of Myocardial Injury in COVID-19

Therapeutic potential of Paclitaxel against COVID-19

The coronavirus disease-2019(COVID-19) was reported in Wuhan, China, in late December 2019 and soon became the most serious global health challenge due to high rate of human-to-human transmission. The severe acute respiratory syndrome coronavirus 2(SARS-CoV-2), is a single-stranded RNA virus and belongs to the large Coronaviridae family. Paclitaxel, an antineoplastic drug extracted from the Tax...

HMGB1: a potential therapeutic target for myocardial ischemia and reperfusion injury.

Myocardial ischemia and reperfusion (I/R) injury is well known in therapy for acute coronary syndrome and open heart surgery. Although reperfusion therapy (such as thrombolysis and percutaneous coronary intervention) is essential for the survival of ischemic tissue, reperfusion itself causes additional cellular injury. I/R could cause local myocardial inflammation, accompanying with apoptosis, ...

A Potential Therapeutic Target in Traumatic Brain Injury

Myocardial ischemia-reperfusion injury: a neglected therapeutic target.

Acute myocardial infarction (MI) is a major cause of death and disability worldwide. In patients with MI, the treatment of choice for reducing acute myocardial ischemic injury and limiting MI size is timely and effective myocardial reperfusion using either thombolytic therapy or primary percutaneous coronary intervention (PPCI). However, the process of reperfusion can itself induce cardiomyocyt...

Succinate metabolism: a new therapeutic target for myocardial reperfusion injury.

Myocardial ischaemia/reperfusion (IR) injury is a major cause of death worldwide and remains a disease for which current clinical therapies are strikingly deficient. While the production of mitochondrial reactive oxygen species (ROS) is a critical driver of tissue damage upon reperfusion, the precise mechanisms underlying ROS production have remained elusive. More recently, it has been demonstr...